AMGEN TO PRESENT AT THE LEERINK PARTNERS 2026 GLOBAL HEALTHCARE CONFERENCE

Amgen (NASDAQ:AMGN) is scheduled to present at the Leerink Partners 2026 Global Healthcare Conference, taking place on Wednesday, March 11, 2026, at 9:20 a.m. ET. The presentation will feature Peter Griffith, Amgen's Chief Financial Officer, and Jasper van Grunsven, Senior Vice President of Rare Disease. Their participation will include a fireside chat aimed at sharing insights about Amgen's ongoing developments.

The conference presentation will be streamed live via a webcast, making it accessible to news media, investors, and the general public. Individuals interested in viewing the presentation can find the webcast on Amgen’s official website, specifically in the Investors section. Furthermore, the event will be archived for replay, ensuring that even those unable to attend in real-time can access the discussions for at least 90 days post-event.

Amgen is a pioneering biotechnology company founded over 45 years ago in Thousand Oaks, California. It has been at the forefront of innovation in medicine, leveraging cutting-edge technology and human genetic data to develop treatments for challenging diseases. The company has a robust pipeline and portfolio that spans various medical conditions, including cancer, inflammatory diseases, rare disorders, as well as cardiovascular and obesity-related conditions.

Acknowledged for its commitment to innovation and positive workplace culture, Amgen has received accolades from prominent publications such as Fast Company and Forbes. As a member of both the Dow Jones Industrial Average and Nasdaq-100 Index, Amgen continues to be recognized as one of the most influential and innovative companies in the healthcare sector. For additional information, visit Amgen’s website or follow their social media channels.

Amgen's upcoming presentation at the Leerink Partners 2026 Global Healthcare Conference presents a significant opportunity for investors to gauge the company's strategic direction, particularly in its efforts towards innovation within the biotechnology sector. Given the current trajectory of biotechnology firms, several key factors merit attention.

Firstly, Amgen's participation in high-profile conferences indicates its commitment to transparency and stakeholder engagement. CFO Peter Griffith's comments may provide insights into the company’s financial health, recent developments, and future projections—key areas that investors should monitor closely. The public nature of these discussions allows analysts to judge market sentiment and expectations surrounding Amgen’s pipeline and product launches.

Moreover, Amgen’s reputation for innovation—demonstrated through its robust pipeline targeting cancer, rare diseases, and other significant health challenges—should be a focal point for investors. As Amgen has established itself as a cornerstone of the biotechnology industry, any revelations during the conference regarding advancements in drug development or collaborations could serve as catalysts for share price movement.

With the stock being part of the Dow Jones Industrial Average and the Nasdaq-100 Index, Amgen represents stability and growth potential. Investors should analyze how Amgen’s strategies align with broader market trends, particularly those surrounding healthcare technology and personalized medicine.

In the context of ongoing market volatility influenced by economic factors and regulatory landscapes, it’s prudent for investors to keep a finger on the pulse of Amgen’s communication from the conference. Monitoring the webcast and subsequent analyses will enable informed investment decisions, particularly for those looking to capitalize on any significant announcements regarding Amgen's future endeavors in healthcare innovation.

In conclusion, maintain a watchful attitude towards Amgen’s developments post-conference, as they could reveal strategic positions that affirm its potential for sustained shareholder value in the volatile biotech landscape.